NCT06319794View on ClinicalTrials.gov

Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

April 2, 2024

Primary Completion Date

June 24, 2025

Study Completion Date

June 24, 2025

Conditions
Actinic Keratosis
Interventions
DRUG

Bimiralisib

Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks

DRUG

Bimiralisib

Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks

Trial Locations (2)

Unknown

University Hospital Basel / Department of Dermatology, Basel

CHUV centre hospitalier universitaire vaudois / Department of Dermatology and Venereology, Lausanne

Sponsors

Lead Sponsor

TORQUR
All Listed Sponsors
lead

TORQUR

INDUSTRY

NCT06319794 - Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis | Biotech Hunter | Biotech Hunter